First randomized trial of a radiopharmaceutical in kidney cancer finds no skeletal benefit
Results of the Alliance for Clinical Trials in Oncology's Phase II RadiCaL trial (Alliance A031801), the first randomized study of a radiopharmaceutical in kidney cancer, found that adding radium-223 to standard care did ...
Aug 18, 2026
0
3









